About
Cancer Immunotherapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalNJ, NY, PA
Team (6)
Andrew Elnatan
Andrew ElnatanSenior Vice President, Regulatory Affairs, CMC, and Quality
Sellas Life Sciences Group
executive
Angelos M
Angelos M. Stergiou, M.D., Sc.D. h.c.President and Chief Executive Officer
Sellas Life Sciences Group
executive
Katherine Bach Kalin
Katherine Bach Kalin
Sellas Life Sciences Group
team_member
Larry W
Larry W. Kwak, M.D., Ph.D.
Sellas Life Sciences Group
team_member
Philip C
Philip C. Amrein, M.D.
Sellas Life Sciences Group
team_member
Robert L
Robert L. Van Nostrand
Sellas Life Sciences Group
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
771
By Phase
PHASE1/PHASE2: 3PHASE3: 1PHASE2: 4
By Status
COMPLETED: 6RECRUITING: 1ACTIVE_NOT_RECRUITING: 1AVAILABLE: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT04588922Lead Sponsor
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
PHASE1/PHASE2Recruiting
160 participants
Started: May 10, 2021 · Completed: Dec 31, 2025
NCT04229979Lead Sponsor
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
PHASE3Active, not recruiting
127 participants
Started: Feb 8, 2021 · Completed: Dec 31, 2026
NCT03761914Lead Sponsor
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
PHASE1/PHASE2Completed
26 participants
Started: Sep 30, 2019 · Completed: Oct 27, 2022
NCT02297698Collaborator
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
PHASE2Completed
100 participants
Started: Oct 31, 2014 · Completed: Dec 31, 2021
NCT01570036Collaborator
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
PHASE2Completed
275 participants
Started: May 21, 2013 · Completed: Sep 28, 2018
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...